PROCEPT BioRobotics | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 83.33 M

LB filings
2025.11.05 22:42
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 83.33 M, beating the estimate of USD 80.77 M.

EPS: As of FY2025 Q3, the actual value is USD -0.38, beating the estimate of USD -0.421.

EBIT: As of FY2025 Q3, the actual value is USD -24.97 M.

Segment Revenue

  • Total Revenue: $83.3 million for the three months ended September 30, 2025, compared to $58.4 million for the same period in 2024, representing a 43% increase. For the nine months ended September 30, 2025, revenue was $231.7 million, compared to $156.3 million in 2024, a 48% increase.
  • System Sales and Leases: $28.1 million for the three months ended September 30, 2025, compared to $22.8 million in 2024, a 23% increase. For the nine months ended September 30, 2025, system sales and leases were $75.6 million, compared to $59.0 million in 2024, a 28% increase.
  • Handpieces and Other Consumables: $49.7 million for the three months ended September 30, 2025, compared to $32.2 million in 2024, a 54% increase. For the nine months ended September 30, 2025, sales were $141.5 million, compared to $88.4 million in 2024, a 60% increase.
  • Service Revenue: $5.5 million for the three months ended September 30, 2025, compared to $3.3 million in 2024, a 64% increase. For the nine months ended September 30, 2025, service revenue was $14.6 million, compared to $8.9 million in 2024, a 65% increase.

Operational Metrics

  • Net Loss: - $21.4 million for the three months ended September 30, 2025, compared to - $21.0 million in 2024. For the nine months ended September 30, 2025, net loss was - $65.7 million, compared to - $72.6 million in 2024.
  • Gross Margin: 65% for the three months ended September 30, 2025, compared to 63% in 2024. For the nine months ended September 30, 2025, gross margin was 65%, compared to 60% in 2024.

Cash Flow

  • Net Cash Used in Operating Activities: - $38.7 million for the nine months ended September 30, 2025, compared to - $66.8 million in 2024.
  • Net Cash Used in Investing Activities: - $7.5 million for the nine months ended September 30, 2025, compared to - $3.2 million in 2024.
  • Net Cash Provided by Financing Activities: $6.8 million for the nine months ended September 30, 2025, compared to $9.6 million in 2024.

Future Outlook and Strategy

  • Core Business Focus: The company plans to grow its install base of robotic systems, targeting approximately 2,700 hospitals in the United States that perform resective BPH procedures. It aims to increase system utilization by establishing Aquablation therapy as the surgical treatment of choice for BPH.
  • Reimbursement Strategy: The company is leveraging Medicare coverage successes to establish additional positive national and regional coverage policies with commercial payors, which is expected to increase system utilization over time.
  • Research and Development: Investment in R&D is focused on developing next-generation technologies and integrating artificial intelligence and machine learning to enhance treatment planning and personalization.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.